Double-blind, placebo-controlled study of luteinising-hormone-releasing-hormone nasal spray in treatment of undescended testes.
In a double-blind, placebo-controlled study, 252 prepubertal boys with 301 undescended testes were treated with luteinising-hormone-releasing-hormone (LHRH), 1.2 mg/day intranasally. After the 8-week double-blind period 10 placebo-treated (8%) and 14 LHRH-treated (9%) testes had completely descended. After a second LHRH course, involving all the subjects in an open study, 48 testes (18%) had descended completely. The lowest success rate (7%) occurred in the youngest age group (1-2 years). Of the successfully treated testes, 75% could be manipulated at least to the scrotal entrance before treatment. In comparison with age-matched controls, the cryptorchid boys' responses to LHRH and human chorionic gonadotropin before treatment did not suggest a deficient hypothalamo-pituitary-gonadal axis or deficient Leydig cell function. After treatment there was no evidence of stimulation of the hypothalamo-pituitary-gonadal axis; serum testosterone did not increase. Surgery was required in 170 patients (196 testes) revealing various anatomical anomalies.
deMuinck Keizer-Schrama
S M
SM
Hazebroek
F W
FW
Matroos
A W
AW
Drop
S L
SL
Molenaar
J C
JC
Visser
H K
HK
D000281:Administration, Intranasal; D000336:Aerosols; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003456:Cryptorchidism / Q000188:drug therapy* / Q000601:surgery; D004311:Double-Blind Method; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D007223:Infant; D008297:Male; D011379:Prognosis; D011897:Random Allocation; D013997:Time Factors
D000336:Aerosols; D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone